Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New schizophrenia drug satisfaction study recruits 300 patients

NCT ID NCT07101094

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 4 times

Summary

This study is tracking 300 adults with schizophrenia in the U.S. who are prescribed a new drug called xanomeline and trospium chloride (X/T). Researchers want to know if patients prefer this drug over their previous treatment and how satisfied they are with it. The study will also look at dosing, side effects, and why some people stop taking the medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
xanomeline and trospium chloride (X/T) therapy
What this could lead to
If successful, this study could show that people with schizophrenia prefer and are more satisfied with this new drug combination, potentially leading to better treatment adherence and quality of life.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove the drug works better than others. Results depend on real-world prescribing and patient reporting, which may be biased or incomplete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adults diagnosed with schizophrenia who initiate treatment with xanomeline and trospium chloride (XT) in the US.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years at index date. * Have a confirmed diagnosis of schizophrenia before index date. * Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. * Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. * Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). * English or Spanish speaking. Exclusion Criteria: * Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. * Evidence of use of XT prior to time of eligibility screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ATP Clinical Research

    RECRUITING

    Costa Mesa, California, 92626, United States

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • C-Trilogy Outreach

    RECRUITING

    Longview, Texas, 75601, United States

  • Continuum Health Providers

    RECRUITING

    Fort Mill, South Carolina, 29708, United States

  • Evanston Hospital

    RECRUITING

    Evanston, Illinois, 60201, United States

  • Hackensack Meridian Health - Carrier Clinic

    RECRUITING

    Belle Mead, New Jersey, 08502, United States

  • Haracec Clinical Research

    RECRUITING

    El Paso, Texas, 79902, United States

  • Local Institution - 0004

    WITHDRAWN

    Catonsville, Maryland, 21228, United States

  • Local Institution - 0008

    COMPLETED

    Belmont, Massachusetts, 02478-1064, United States

  • Local Institution - 0017

    WITHDRAWN

    Bel Air, Maryland, 21015, United States

  • Local Institution - 0019

    NOT_YET_RECRUITING

    Miami, Florida, 33176, United States

  • Local Institution - 0020

    NOT_YET_RECRUITING

    Grand Island, Nebraska, 68803, United States

  • Lumos Clinical Research Center

    RECRUITING

    San Jose, California, 95124, United States

  • Mayflower Clinical

    RECRUITING

    South Dartmouth, Massachusetts, 02747, United States

  • New Dawn Psychiatric Services, PLLC

    RECRUITING

    Kinston, North Carolina, 28501, United States

  • New Dimension Group

    RECRUITING

    Rose Hill, North Carolina, 28458, United States

  • Omaha Insomnia and Psychiatric Services

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Radial - Manhattan

    RECRUITING

    New York, New York, 10018, United States

  • The Johns Hopkins Hospital

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Westlake Brain Health

    RECRUITING

    Westlake, Ohio, 44145, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.